Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome
Key facts
- Who runs it
- Kafrelsheikh University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- NCT07563647
- PACTR202604903325533
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 60 people enrolled
- Started
- 5 May 2025
- Ended
- 17 Mar 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tadalafil 5 mg
- SGLT-2 inhibitor
- Tadalafil plus SGLT2 inhibitors
- Record updated
- 4 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Male patients aged ≥18 years
- History of sexual activity within the past 6 months
- Erectile dysfunction for at least 3 months (defined as IIEF-6 score ≤25)
- Diagnosed with metabolic syndrome
Who cannot take part
- * Left ventricular systolic dysfunction (EF less than 50%); Recent myocardial infarction (within 1 month); Moderate to severe valvular heart disease (stenosis or regurgitation); Renal failure (eGFR <20 ml/min); Major pelvic surgery; Significant central nervous system injury (e.g., spinal cord injury); Endocrine disorders (hypothyroidism, hypogonadism); Premature ejaculation; Current balanitis or urogenital infections; History of orthostatic hypotension; Any contraindications to tadalafil or SGLT2 inhibitors
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Metabolic syndrome is associated with an increased risk of cardiovascular disease and is commonly accompanied by erectile dysfunction and subclinical cardiac dysfunction. Erectile dysfunction and left ventricular diastolic dysfunction may share common underlying mechanisms, including endothelial dysfunction and microvascular impairment.
Read full original descriptionShow less
This study aims to investigate the association between erectile dysfunction and left ventricular diastolic dysfunction in men with metabolic syndrome, and to evaluate the effects of different treatment strategies, including tadalafil and SGLT2 inhibitors, on both erectile function and cardiac diastolic function.
Participants will be randomly assigned to receive tadalafil, an SGLT2 inhibitor, or a combination of both for a duration of three months. Clinical, echocardiographic, and functional assessments will be performed at baseline and after treatment.
The results of this study may improve understanding of the link between cardiovascular and sexual dysfunction and help guide therapeutic approaches in this patient population.
The 3 groups in the trial
- Tadalafil GroupExisting treatment, for comparison
Participants received tadalafil 5 mg orally once daily for 3 months. Erectile function, left ventricular diastolic function, and metabolic parameters were assessed at baseline and after completion of treatment.
Treatment: Tadalafil 5 mg
- SGLT2 inhibitors groupTreatment being tested
Participants received SGLT2 inhibitors (dapagliflozin or empagliflozin) 10 mg orally once daily for 3 months. Erectile function, left ventricular diastolic function, and metabolic parameters were assessed at baseline and after completion of treatment.
Treatment: SGLT-2 inhibitor
- Combination therapyTreatment being tested
Participants received combination therapy with tadalafil 5 mg once daily plus SGLT2 inhibitors 10 mg once daily for 3 months. Erectile function, left ventricular diastolic function, and metabolic parameters were assessed at baseline and after completion of treatment.
Treatment: Tadalafil plus SGLT2 inhibitors
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Allocation-concealed, Assessor-blinded, Parallel-group Trial Evaluating the Association Between Erectile Dysfunction and Left Ventricular Diastolic Dysfunction and Comparing the Effects of Tadalafil, SGLT2 Inhibitors, and Their Combination in Patients With Metabolic Syndrome.
- Record updated
- 4 May 2026